

Markers Of Oxidative Damage Are Not Elevated In Otherwise Healthy Individuals With The Metabolic Syndrome

^{1,2}Raymond CS Seet, MD; ¹Chung-Yung J Lee, PhD; ^{1,2}Erle CH Lim, MD; ²Amy ML Quek, MD; ³Shan-Hong Huang, MSc; ^{1,2}Chin-Meng Khoo, ³Barry Halliwell, DSc

¹Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore

²Department of Medicine, National University Hospital, Singapore

³Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore

ONLINE APPENDIX

Supplemental Table 1. Clinical characteristics, risk components of metabolic syndrome and markers of oxidative damage

| | Male (n=87) | Female (n=92) | P-values |
|-----------------------------------|-------------------|-------------------|----------|
| Age (years) | 42.8 (13.7) | 43.9 (13.7) | 0.558 |
| Race, Chinese (%) | 70 (81%) | 72 (78%) | 0.610 |
| Systolic blood pressure (mmHg) | 130 (15) | 122 (14) | 0.011 |
| Diastolic blood pressure (mmHg) | 80 (12) | 78 (9) | 0.374 |
| Body mass index | 24.2 (3.5) | 23.1 (4.1) | 0.030 |
| High-density lipoprotein (mmol/l) | 1.29 (0.38) | 1.61 (0.44) | <0.001 |
| Triglyceride (mmol/l) | 1.27 (0.65) | 1.05 (0.73) | 0.036 |
| Glucose (mmol/l) | 5.13 (1.25) | 4.75 (1.02) | 0.028 |
| Insulin (pmol/l) | 8.40 (5.70-16.20) | 7.10 (5.20-12.80) | 0.932 |
| HOMA-IR | 1.72 (1.14-3.55) | 1.47 (1.04-2.68) | 0.653 |
| Risk factor components of MetS | | | |
| None | 41 (47%) | 58 (63%) | 0.048 |
| 1-2 | 39 (45%) | 27 (29%) | 0.010 |
| 3 and more | 7 (8%) | 7 (8%) | 0.805 |

Data were expressed as absolute numbers (percentage), mean (standard deviation) or median (inter-quartile range) Abbreviations: HOMA-IR=homeostatic model assessment-insulin resistance index, MetS=metabolic syndrome

Supplemental Table 2. Comparison between risk factors components of the metabolic syndrome in relation to markers of oxidative damage, high-sensitivity C-reactive protein and enzymatic activities in males

| | Number of Risk Factor Components of the Metabolic Syndrome | | | P-trend |
|---------------------------------------------|------------------------------------------------------------|---------------------|--------------------------|---------|
| | None (n=41) | One or Two (n=39) | Metabolic syndrome (n=7) | |
| Age (years) | 40.05 (14.03) | 45.69 (13.37) | 42.86 (8.57) | 0.254 |
| Race, Chinese (%) | 32 (78%) | 29 (74%) | 5 (71%) | 0.858 |
| Insulin (pmol/l) | 9.07 (6.49) | 11.79 (6.97) | 29.26 (28.36) | 0.001 |
| HOMA-IR | 1.94 (1.42) | 2.74 (1.83) | 4.69 (2.00) | 0.001 |
| Blood markers | | | | |
| Arachidonate (AA) (ug/ml) | 95.74 (26.63) | 87.25 (16.86) | 81.79 (19.01) | 0.080 |
| F₂-IsoPs | | | | |
| Esterified (ng/ml) | 0.30 (0.09) | 0.31 (0.13) | 0.24 (0.97) | 0.474 |
| Free (ng/ml) | 0.06 (0.02) | 0.06 (0.02) | 0.07 (0.02) | 0.155 |
| Esterified/AA (ng/ug) | 3.33 (1.30) | 3.64 (1.63) | 3.02 (1.48) | 0.872 |
| HETEs | | | | |
| Esterified (ng/ml) | 22.42 (8.88) | 23.72 (9.43) | 18.60 (4.99) | 0.711 |
| Free (ng/ml) | 2.18 (0.95) | 2.33 (1.63) | 2.48 (0.55) | 0.493 |
| Esterified/AA (ng/ug) | 0.25 (0.13) | 0.28 (0.11) | 0.24 (0.09) | 0.646 |
| Cholesterol (mg/ml) | 5.08 (0.84) | 5.45 (1.06) | 5.10 (0.85) | 0.326 |
| COPs (ng/ml) | | | | |
| 7 α -OH cholesterol | 20.56 (7.11) | 28.41 (18.81) | 25.01 (26.45) | 0.069 |
| 7 β -OH cholesterol | 4.38 (1.65) | 4.41 (1.85) | 4.71 (1.61) | 0.707 |
| 24-OH cholesterol | 16.97 (17.52) | 15.76 (10.87) | 17.75 (11.36) | 0.914 |
| 27-OH cholesterol | 69.33 (22.00) | 70.49 (28.41) | 64.28 (22.92) | 0.820 |
| COPs/cholesterol (ng/mg) | | | | |
| 7 α -OH cholesterol | 4.15 (1.63) | 5.50 (3.42) | 5.02 (5.15) | 0.113 |
| 7 β -OH cholesterol | 0.89 (0.43) | 0.82 (0.35) | 0.93 (0.32) | 0.783 |
| 24-OH cholesterol | 3.43 (3.32) | 3.05 (2.36) | 3.57 (2.37) | 0.814 |
| 27-OH cholesterol | 13.94 (4.70) | 13.30 (5.88) | 13.19 (6.44) | 0.607 |
| Uric acid, uM | 353.51 (106.81) | 382.97 (111.89) | 364.17 (107.77) | 0.420 |
| Allantoin, uM | 2.06 (0.72) | 1.79 (0.69) | 1.72 (0.75) | 0.099 |
| GGT (U/l) | 20.90 (15.00-34.65) | 29.80 (20.90-49.13) | 25.90 (20.90-39.70) | 0.130 |
| Hs-CRP (mg/l) | 0.72 (0.43-1.26) | 1.29 (0.51-2.32) † | 1.14 (0.92-5.49) † | <0.001 |
| PAFAH activities (nmol/min/ml) | 14.27 (4.48) | 14.09 (4.80) | 15.85 (2.11) | 0.621 |
| PLA ₂ activities (mol/min/ml) | 7.23 (0.96) | 7.42 (2.04) | 6.59 (0.93) | 0.714 |
| Urine markers | | | | |
| Unadjusted (ng/ml) | | | | |
| Total IsoPs | 8.02 (6.08) | 9.10 (5.51) | 8.99 (5.67) | 0.472 |
| 8-iso-F ₂ -IsoPs | 0.79 (1.10) | 0.69 (0.41) | 0.75 (0.24) | 0.693 |
| 2,3-dinor-F ₂ -IsoPs | 2.81 (1.94) | 2.67 (2.14) | 1.85 (1.46) | 0.338 |
| 2,3-dinor-5,6-dihydro-F ₂ -IsoPs | 4.27 (4.45) | 4.27 (4.45) | 6.39 (5.13) | 0.103 |
| 8-OHdG | 2.27 (1.35) | 2.64 (1.89) | 3.85 (2.48) | 0.093 |
| Adjusted for creatinine (ng/mg) | | | | |
| Total IsoPs | 7.53 (2.77) | 7.43 (3.29) | 6.73 (1.75) | 0.586 |
| 8-iso-F ₂ -IsoPs | 0.51 (0.28) | 0.46 (0.28) | 0.30 (0.11) | 0.086 |
| 2,3-dinor-F ₂ -IsoPs | 3.34 (2.03) | 3.34 (2.03) | 2.07 (1.69) | 0.195 |
| 2,3-dinor-5,6-dihydro-F ₂ -IsoPs | 4.00 (2.45) | 5.77 (4.41) | 6.40 (5.13) | 0.681 |
| 8-OHdG | 0.51 (0.28) | 0.46 (0.28) | 0.30 (0.11) | 0.086 |

Data were expressed as absolute numbers (percentage), mean (standard deviation) or median (inter-quartile range) † denotes significant difference as compared with those with no risk factor (using unpaired t-test)

Abbreviations: F₂-IsoPs=F₂-isoprostanes, HETEs=hydroxyeicosatetraenoic acid, COPs=cholesterol oxidation products, 8-OHdG= 8-hydroxydeoxyguanosine, PLA₂=phospholipase A₂ activities, PAF-AH=platelet activating factor-acetylhydrolase activities, GGT=gamma glutamyltransferase, hs-CRP=high-sensitivity C-reactive protein

Supplemental Table 3. Comparison between risk factors components of the metabolic syndrome in relation to markers of oxidative damage, high-sensitivity C-reactive protein and enzymatic activities in females

| | Number of Risk Factor Components of the Metabolic Syndrome | | | P-trend |
|---------------------------------------------|------------------------------------------------------------|---------------------|--------------------------|---------|
| | None (n=58) | One or Two (n=27) | Metabolic syndrome (n=7) | |
| Age (years) | 44.29 (13.70) | 42.74 (15.25) | 46.29 (7.30) | 0.985 |
| Race, Chinese (%) | 52 (90%) | 23 (85%) | 6 (86%) | 0.925 |
| Insulin (pmol/l) | 7.31 (4.86) | 17.51 (17.55) † | 21.29 (8.81) † | <0.001 |
| HOMA-IR | 1.49 (1.13) | 3.39 (3.02) † | 4.89 (1.88) † | <0.001 |
| Blood markers | | | | |
| Arachidonate (AA) (ug/ml) | 100.92 (26.86) | 94.39 (21.61) | 91.23 (19.53) | 0.184 |
| F₂-IsoPs | | | | |
| Esterified (ng/ml) | 0.33 (0.11) | 0.32 (0.15) | 0.25 (0.11) | 0.128 |
| Free (ng/ml) | 0.05 (0.02) | 0.05 (0.02) | 0.06 (0.02) | 0.939 |
| Esterified/AA (ng/ug) | 3.45 (1.21) | 3.40 (1.46) | 2.71 (0.99) | 0.261 |
| HETEs | | | | |
| Esterified (ng/ml) | 21.86 (7.14) | 21.62 (7.54) | 20.93 (5.81) | 0.755 |
| Free (ng/ml) | 2.67 (1.44) | 2.79 (1.97) | 2.21 (1.05) | 0.728 |
| Esterified/AA (ng/ug) | 0.23 (0.11) | 0.24 (0.10) | 0.24 (0.08) | 0.813 |
| Cholesterol (mg/ml) | 5.41 (1.06) | 5.48 (1.08) | 4.91 (0.71) | 0.493 |
| COPs (ng/ml) | | | | |
| 7 α -OH cholesterol | 18.78 (6.73) | 17.88 (7.84) | 25.40 (12.80) | 0.217 |
| 7 β -OH cholesterol | 4.78 (2.78) | 4.34 (2.29) | 4.13 (1.81) | 0.382 |
| 24-OH cholesterol | 14.58 (6.72) | 15.01 (8.68) | 17.47 (18.62) | 0.475 |
| 27-OH cholesterol | 58.17 (2041) | 56.78 (17.54) | 48.60 (10.08) | 0.282 |
| COPs/cholesterol (ng/mg) | | | | |
| 7 α -OH cholesterol | 3.59 (1.62) | 3.37 (1.54) | 5.12 (2.30) | 0.198 |
| 7 β -OH cholesterol | 0.89 (0.47) | 0.82 (0.45) | 0.83 (0.29) | 0.554 |
| 24-OH cholesterol | 2.76 (1.29) | 2.88 (1.94) | 3.41 (3.16) | 0.386 |
| 27-OH cholesterol | 11.04 (4.27) | 10.71 (3.99) | 10.01 (2.37) | 0.520 |
| Uric acid (uM) | 301.55 (138.80) | 310.46 (148.44) | 435.43 (244.44) | 0.090 |
| Allantoin (uM) | 1.93 (0.67) | 1.72 (0.65) | 2.01 (0.98) | 0.619 |
| GGT (U/l) | 11.35 (9.90-15.20) | 13.20 (10.50-22.80) | 21.20 (15.80-24.30) † | 0.002 |
| Hs-CRP (mg/l) | 0.49 (0.30-1.01) | 0.80 (0.56-1.41) | 2.93 (2.13-10.86) † | <0.001 |
| PAFAH activities (nmol/min/ml) | 13.24 (4.33) | 14.67 (3.60) | 11.43 (3.20) | 0.947 |
| PLA ₂ activities (mol/min/ml) | 6.32 (0.97) | 6.62 (0.83) | 3.25 (0.36) | 0.515 |
| Urine markers | | | | |
| Unadjusted (ng/ml) | | | | |
| Total IsoPs | 15.56 (12.34) | 11.08 (7.15) | 13.36 (9.62) | 0.184 |
| 8-iso-F ₂ -IsoPs | 0.57 (0.41) | 0.43 (0.34) | 0.47 (0.21) | 0.164 |
| 2,3-dinor-F ₂ -IsoPs | 3.58 (2.52) | 2.83 (1.66) | 5.15 (3.13) | 0.663 |
| 2,3-dinor-5,6-dihydro-F ₂ -IsoPs | 11.49 (11.94) | 7.80 (6.30) | 7.73 (1.09) | 0.133 |
| 8-OHdG | 2.16 (1.44) | 1.96 (2.18) | 2.75 (2.28) | 0.981 |
| Adjusted for creatinine (ng/mg) | | | | |
| Total IsoPs | 7.87 (3.11) | 8.15 (2.94) | 9.59 (1.54) | 0.207 |
| 8-iso-F ₂ -IsoPs | 0.59 (0.33) | 0.52 (0.32) | 0.44 (0.24) | 0.173 |
| 2,3-dinor-F ₂ -IsoPs | 2.28 (1.86) | 2.51 (1.82) | 4.07 (1.70) † | 0.043 |
| 2,3-dinor-5,6-dihydro-F ₂ -IsoPs | 5.01 (2.49) | 5.11 (2.64) | 5.08 (2.20) | 0.875 |
| 8-OHdG | 2.08 (0.98) | 1.84 (0.85) | 2.55 (1.04) | 0.828 |

Data were expressed as absolute numbers (percentage), mean (standard deviation) or median (inter-quartile range) † denotes significant difference as compared with those with no risk factor (using unpaired t-test)

Abbreviations: F₂-IsoPs=F₂-isoprostanes, HETEs=hydroxyeicosatetraenoic acid, COPs=cholesterol oxidation products, 8-OHdG= 8-hydroxydeoxyguanosine, PLA₂=phospholipase A₂ activities, PAF-AH=platelet activating factor-acetylhydrolase activities, GGT=gamma glutamyltransferase, hs-CRP=high-sensitivity C-reactive protein

Supplemental Table 4. Age-adjusted correlates of Homeostasis Model Assessment Insulin Resistance (HOMA-IR) index

| | Male | | Female | |
|---------------------------------------------|------------------------|----------|------------------------|----------|
| | Regression coefficient | P-values | Regression coefficient | P-values |
| Plasma markers | | | | |
| F ₂ -IsoPs | | | | |
| Esterified (ng/ml) | -0.083 | 0.469 | -0.038 | 0.728 |
| Free (ng/ml) | 0.121 | 0.292 | -0.051 | 0.638 |
| Esterified/AA (ng/ug) | -0.033 | 0.775 | -0.012 | 0.913 |
| HETEs | | | | |
| Esterified (ng/ml) | -0.061 | 0.597 | 0.408 | 0.684 |
| Free (ng/ml) | -0.083 | 0.472 | -0.130 | 0.233 |
| Esterified/AA (ng/ug) | -0.049 | 0.669 | 0.044 | 0.689 |
| COPs (ng/ml) | | | | |
| 7 α -OH cholesterol | 0.336 | 0.004 | 0.238 | 0.290 |
| 7 β -OH cholesterol | -0.052 | 0.653 | 0.339 | 0.001 |
| 24-OH cholesterol | 0.000 | 0.999 | 0.181 | 0.094 |
| 27-OH cholesterol | -0.104 | 0.371 | -0.100 | 0.358 |
| COPs/cholesterol (ng/mg) | | | | |
| 7 α -OH cholesterol | 0.359 | 0.001 | 0.136 | 0.211 |
| 7 β -OH cholesterol | -0.024 | 0.832 | 0.320 | 0.003 |
| 24-OH cholesterol | 0.017 | 0.887 | 0.119 | 0.278 |
| 27-OH cholesterol | -0.081 | 0.479 | -0.179 | 0.106 |
| Uric acid (uM) | 0.068 | 0.564 | 0.221 | 0.046 |
| Allantoin (uM) | -0.141 | 0.237 | -0.036 | 0.759 |
| GGT (U/l) | -0.020 | 0.863 | 0.199 | 0.062 |
| Hs-CRP (mg/l) | 0.500 | <0.001 | 0.285 | 0.007 |
| PAFAH activities (nmol/min/ml) | -0.014 | 0.903 | 0.032 | 0.764 |
| PLA ₂ activities (mol/min/ml) | -0.062 | 0.591 | 0.128 | 0.247 |
| | | | | |
| Urine markers | | | | |
| Unadjusted (ng/ml) | | | | |
| Total F ₂ -IsoPs | 0.049 | 0.674 | -0.056 | 0.607 |
| 8-iso-F ₂ -IsoPs | -0.033 | 0.779 | -0.056 | 0.605 |
| 2,3-dinor- F ₂ -IsoPs | -0.200 | 0.079 | 0.062 | 0.571 |
| 2,3-dinor-5,6-dihydro-F ₂ -IsoPs | 0.174 | 0.132 | -0.075 | 0.491 |
| 8-OHdG | 0.150 | 0.264 | 0.147 | 0.239 |
| Adjusted for creatinine (ng/mg) | | | | |
| Total F ₂ -IsoPs | -0.130 | 0.273 | 0.141 | 0.205 |
| 8-iso-F ₂ -IsoPs | -0.130 | 0.265 | -0.151 | 0.167 |
| 2,3-dinor-F ₂ -IsoPs | -0.335 | 0.004 | 0.102 | 0.351 |
| 2,3-dinor-5,6-dihydro-F ₂ -IsoPs | 0.077 | 0.502 | 0.101 | 0.351 |
| 8-OHdG | -0.156 | 0.243 | 0.135 | 0.300 |

Abbreviations: F₂-IsoPs= F₂-isoprostanes, HETEs=hydroxyeicosatetraenoic acid, COPs=cholesterol oxidation products, GGT=gamma glutamyltransferase, hs-CRP=high-sensitivity C-reactive protein, PAF-AH=platelet activating factor-acetylhydrolase activities, PLA₂=phospholipase A₂ activities, 8-OHdG= 8-hydroxydeoxyguanosine